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Background: Drug-related adverse events (AEs) are reported to be common amongst patients receiving outpatient
parenteral antimicrobial therapy (OPAT). However, comparative data regarding intravenous (iv) catheter-related
AEs are lacking.
Objectives: To compare drug- and iv catheter-related AEs from a large UK OPAT centre.
Patients and methods: We reviewed 544 OPAT episodes [median (IQR) age: 57 (39–71) years, 60% male, 13%
with diabetes] with a median (IQR) duration of 7 (2–18) days. Clinically significant drug- and iv catheter-related
AEs were calculated as a percentage of OPAT episodes with an AE and also as AEs per 1000 iv drug/catheter
days.
Results: Drug-related AEs complicated 13 (2.4%) OPAT episodes at 1.7 (95% CI 0.9–2.9) per 1000 drug days.
Catheter-related AEs occurred more frequently, complicating 32 (5.9%) episodes at 5.7 (95% CI 4.2–7.9) per
1000 iv catheter days (v2 test for difference in AE rate: P,0.001). Non-radiologically guided midline catheters
were associated with the most frequent AEs (n"23) at 15.6 (95% CI 10.3–23.4) per 1000 iv catheter days com-
pared with other types of iv catheters (HR 8.4, 95% CI 2.4–51.9, P,0.004), and self-administration was associ-
ated with a higher rate of catheter-related AEs at 12.0 (95% CI 6.0–23.9) per 1000 iv catheter days (HR 4.15, 95%
CI 1.7–9.1, P"0.007).
Conclusions: Clinically significant iv catheter-related AEs occurred more frequently than drug-related AEs, espe-
cially when using non-radiologically guided midline catheters. Regular review of the need for iv therapy and
switching to oral antimicrobials when appropriate is likely to minimize OPAT-related AEs.
Introduction
Outpatient parenteral antimicrobial therapy (OPAT) prevents admis-
sion to hospital and facilitates early discharge.1 The clinical efficacy
of OPAT compared with inpatient care appears equivalent,1 placing
an onus on ensuring that OPAT services are delivered safely, by
quantifying the rate of adverse events (AEs), including those related
to the use of intravenous (iv) catheters, and the antimicrobials
administered.2 Both have been widely reported but often as an abso-
lute proportion over the entirety of the OPAT care episode,3–6 which
is overly simplistic given the heterogeneity of OPAT indications, as
risk is clearly related to the duration of the OPAT care episode.7,8
In a recent US-based study, clinically significant drug-related
AEs complicated 18% of OPAT care episodes at a rate of 2.24
events per 1000 OPAT care days. Data on iv catheter-related AEs in
this cohort were not provided.9 A separate US cohort reported
catheter-related AEs at a rate of 4.29 per 1000 OPAT days, but did
not report drug-related AEs.8 In contrast, a large UK-based retro-
spective study estimated drug-related and catheter-related AEs at
3.8 and 0.2 per 1000 OPAT care days, respectively.10 In a smaller
Swiss cohort the rate of drug-related AEs was similar (4 per
1000 OPAT treatment days) with catheter-related AEs again
occurring less frequently at 2.4 per 1000 OPAT treatment days.11
Drug-related AEs are influenced by many factors, including the
choice of antimicrobials in local formularies,12 and some drugs,
such as vancomycin, are recognized to have relatively high rates of
AEs.13 A risk of AEs is also associated with iv catheters: tunnelled
and peripherally inserted central catheters (PICCs) extend to the
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superior vena cava, require radiologically guided insertion and may
precipitate central venous thrombosis. Midlines extend no further
than the axillary vein and some can be inserted without radiologic-
al guidance.14 Although midlines are reported to carry greater AE
risks,15,16 in the OPAT setting this has not been consistently
observed.7,13 The Swiss study only included patients using either
peripheral cannulae or PICCs,11 and one of the UK studies only
included a small proportion (,3%) of patients using midlines.10
In this study, we used prospective data from a large UK OPAT
care centre to fully characterize the rate of both drug- and
catheter-related AEs. We hypothesized that it is catheter- and not
drug-related AEs that drive the greatest risk to the patient during
the OPAT episode.
Patients and methods
Ethics
The study was approved by the Audit and Research Committee at the
Hospital for Tropical Diseases, University College London Hospitals (UCLH),
which stated that, as this was a retrospective review of routine clinical data
being analysed for service development purposes, further formal ethics ap-
proval was not required.
Patient cohort and data extraction
We reviewed the case records of patients who were assessed by the OPAT
team at UCLH between January 2015 and September 2017. Patients were
accepted onto the OPAT service only after clinical review by at least one in-
fection specialist on any day of the week. Patients’ indication for continued
iv therapy was reviewed in clinics throughout the week at clinicians’ discre-
tion, but all OPAT patients were also reviewed weekly by a multidisciplinary
team, including at least two infection specialists, where the indication for iv
therapy was again reviewed and outcomes determined. Data were an-
onymously extracted from the OPAT electronic Clinical Infectious Diseases
(elCID) database at UCLH.17
Clinical definitions
OPAT outcomes were defined using the standardized National
Outcome Registry System (NORS) definitions (http://opatregistry.com/).
Clinically significant drug-related AEs were defined as hospital readmis-
sions or change of OPAT antimicrobial drug owing to toxicity or
Clostridioides (Clostridium) difficile infection. Catheter-related AEs were
defined as hospital readmission related to an iv catheter complication
or iv catheter blockage, displacement, extravasation or phlebitis requir-
ing iv catheter change. Readmission was defined as an admission to
hospital during the OPAT period.
Statistical analysis
We calculated the duration of OPAT care episodes from the date of dis-
charge from inpatient stay to the OPAT service. Missing catheter insertion
dates were imputed to be the start of the OPAT episode, or the day follow-
ing removal of the previous catheter in the case of catheter replacement.
Missing catheter removal dates were imputed to be the end of the OPAT
episode, or the day preceding new catheter insertion. We calculated the
proportion of OPAT episodes in which a drug- or iv catheter-related AE
occurred and the rate of AEs per 1000 iv catheter/drug days. We fitted a
Poisson regression model to assess the risk of AEs controlling for both type
of iv catheter and whether OPAT was administered by nursing staff or self-
administered. Statistical analysis was performed using R v3.4.2.
Results
OPAT patient cohort and clinical outcomes
Over a 32 month period, the OPAT service received 781 patient
referrals, of which 243 were not accepted, most commonly (158,
65%) owing to infection specialist assessment that iv antimicro-
bials were not indicated, including the availability of oral alterna-
tives (Table S1, available as Supplementary data at JAC Online).
Consequently, we present data from 538 patients resulting in 544
episodes of OPAT patient care. The median age was 57 (IQR 39–
71) years, 60% of the cohort was male and 13% had diabetes mel-
litus. The median duration of an OPAT care episode was 7 days
(IQR 2–18), but was dependent on the OPAT indications, the com-
monest being skin and soft tissue infections (32% of episodes)
(Table S2). The three most frequent antimicrobials used were cef-
triaxone, teicoplanin and ertapenem (Table S3) and midline cathe-
ters accounted for over half the total indwelling iv catheter
duration (Table S4). Overall, OPAT was judged to be a full/partial
success in 93% of episodes. A total of 35 patients (6.4%) required
readmission and there were two deaths (0.4%).
Adverse events
Drug-related AEs complicated 13 (2.4%) OPAT episodes at a rate of
1.7 (95% CI 0.9–2.9) per 1000 drug days (Table S5). There was no dif-
ference in the AE rate between b-lactam versus non-b-lactam drugs
(Table 1). Rash was the commonest drug-related AE, occurring in
eight episodes of OPAT care (62% of drug-related AE) (Table S5).
Catheter-related AEs occurred significantly more frequently than
drug-related AEs (n"39 in total), complicating 32 (5.9%) episodes
at a rate of 5.7 (95% CI 4.2–7.9) per 1000 iv catheter days (v2 test for
difference in the rate of drug- and iv catheter-related AEs: P,0.001)
(Table 1 and Figure 1a). The commonest iv catheter-related AEs
were extravasation (13, 33%), blockage (8, 21%) and displacement
(8, 21%) (Table S6). In unadjusted analyses, the rate of AEs was
highest for non-radiologically guided midline catheters [n"23, 59%
at 15.6 (95% CI 10.3–23.4) per 1000 iv catheter days] (Figure 1b). In
unadjusted analyses, self-administration was associated with more
frequent iv catheter-related AEs [12.0 (95% CI 6.0–23.9) per
1000 OPAT days] versus nurse-administered [4.8 (95% CI 3.3–7.0)]
or mixed administration [8.5 (95% CI 3.3–23.5)] (Tables 1 and S7). In
the adjusted Poisson regression analysis both non-radiologically
guided midline catheters (HR 8.4, 95% CI 2.4–51.9, P,0.004) and
self-administration (HR 4.15, 95% CI 1.7–9.1, P"0.007) remained
associated with a higher rate of iv catheter-related AEs.
Discussion
Delivery of any service obligates clinicians to minimize the risks
posed to patients. In this study involving more than 500 OPAT epi-
sodes, we have shown that, in contrast to previous observa-
tions,10,11 iv catheter-related AEs were the main drivers of AEs,
whereas drug-related AEs occurred less frequently than previously
described.9,11
The higher rate of AEs associated with iv catheters in our cohort
was largely driven by the use of midlines in general and specifically
midline catheters that are shorter and less secured, but which can
be inserted without radiological guidance in the outpatient set-
ting.14 Secured iv catheters, such as PICCs and tunnelled central
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venous catheters require radiological input for insertion, but have
lower rates of complications compared with unsecured mid-
lines.7,13,15,16 Crucially, previous studies that directly compared
drug- and catheter-related AE rates included few patients using
midlines for iv access.10,11
We also observed a higher rate of catheter-related AEs for self-
administration of OPAT which remained significant after adjusting
for the catheter type. Previous studies have not consistently identi-
fied an increased risk for self-OPAT,7,10 but our findings overall
suggest that the choices of iv access device and method for OPAT
drug administration represent a trade-off between elevated AE
risks and the convenience associated with non-radiologically
guided midline insertion and self-administration.18
The drug-related AE rate in our study (1.7 per 1000 OPAT days)
was lower than in a recent US-based case series (2.24 per 1000
OPAT days),9 in part driven by the use of vancomycin, an antibiotic
associated with a high AE rate.13 In contrast, teicoplanin, which is
not routinely available in the USA, was almost exclusively the
Table 1. Antimicrobial- and iv catheter-related OPAT AEs
Usage (no. of episodes) AEs, N (%)a AE rate per 1000 days (95% CI)b
Antimicrobial drugs used antimicrobial drug-related antimicrobial drug-related
all antimicrobials 688 13 (1.9) 1.7 (0.9–2.9)
b-lactam antimicrobials 517 10 (1.9) 1.7 (0.2–12.3)
non-b-lactam antimicrobials 171 3 (1.8) 1.2 (0.4–3.6)
iv catheters used iv catheter-related iv catheter-related
all catheters 576 32 (5.6) 5.7 (4.2–7.9)
non-radiologically guided midline catheters 118 23 (19.5) 15.6 (10.3–23.4)
radiologically guided midline catheters 155 21 (13.5) 0.67 (0.43–1.02)
PICC 32 7 (21.9) 0.45 (0.19–1.1)
peripheral cannulae 261 3 (1.1) 2.38 (0.77–7.4)
tunnelled central venous line catheters 10 0 (0) —
Method of OPAT drug administration iv catheter-related iv catheter-related
self-administration 30 8 (27) 12.0 (6.0–23.9)
mixed administration 20 4 (20) 8.5 (3.3–23.5)
nurse-administered 488 27 (5.5) 4.8 (3.3–7.0)
aAE percentages as a proportion of the number of episodes of use for each variable.
bAE rates per 1000 days of OPAT care, unadjusted for other variables.
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Figure 1. Rate of OPAT-related AEs. Kaplan–Meier plots demonstrating (a) AEs attributed to either drugs or iv catheters and (b) catheter-related AEs
stratified by route of iv access. AEs are indicated by censored events on plots.
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glycopeptide of choice in our cohort, supporting its use as an alter-
native to vancomycin to deliver safe and effective OPAT care.19
This is backed up by the high OPAT success rate observed, although
it is noteworthy that the majority of OPAT episodes in our cohort
commenced after initiation of iv antimicrobial therapy as an in-
patient, which may have both impacted significantly on clinical
outcomes as well as reduced early drug-related AEs.
Our study had a number of strengths, including a large number
of cases and a heterogeneous patient cohort, generalizable to
other centres, where the use of iv antimicrobials was subject to
physician stewardship both prior to access to OPAT services and
during OPAT care. We also observed high OPAT success rates
(.85%) comparable with those documented in previous studies.1
Nevertheless, this was a cohort study at risk of unrecognized con-
founding bias despite the prospective and systematic data collec-
tion. Secondly, despite the large cohort size, the numbers
remained low for each OPAT indication, limiting detailed multivari-
able analyses, including the interplay between the choice of anti-
microbial and the choice of iv catheter. Thirdly, despite the use of
national reporting standards for AEs, we cannot exclude gradual
reporting bias over time, although this should not have differed be-
tween drug- and catheter-related AEs. Finally, catheter-related AE
rates were calculated over the entire study period, during which
expertise of OPAT staff inserting non-radiologically guided midline
catheters may have improved.
In summary, we present evidence from a large prospective co-
hort of OPAT patients to demonstrate that iv catheter-related AEs
exceed those associated with parenteral antimicrobial drugs. As
such, we recommend regular and efficient stewardship of iv anti-
microbials,20 irrespective of class, both at referral to and during
OPAT care, in order to minimize the duration of iv catheter use and
the consequent harm to patients.
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